August 22, 2016
Summit Keeps Climbing
It's taking a long time, but it's happening! Summit Therapeutics, a UK-based company we began supporting nine years ago, is making significant progress on its experimental…
June 22, 2016
Update on the HT-100 program
Earlier this week at the annual PPMD Connect Conference in Orlando, Akashi Therapeutics CMO Dr. Diana Escolar presented an update on the HT-100 program. "We…
May 22, 2016
We remain active on other medical research fronts
While we aggressively advocate for the approval of eteplirsen, we remain active on other medical research fronts. It's important to remember that eteplirsen helps 13%…
April 12, 2016
Meet the Impact Initiative
You probably already know that Charley's Fund is supporting the development of several new medicines to slow or halt Duchenne's deadly progression. Our goal is…
October 15, 2007
AVI BioPharma Receives Major Research and Development Grant From Charley’s Fund for Duchenne Muscular Dystrophy
AVI BioPharma Receives Major Research and Development Grant From Charley’s Fund for Duchenne Muscular Dystrophy $2.45 Million Will Fund Research and Product Development Program PORTLAND,…
June 6, 2006
Research Update
When we incorporated Charley’s Fund in November 2004, I had no idea that we could have an impact on the medical research in such a…